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ABSTRACT
A PCR restriction fragment length polymorphism assay was used to analyse single-nucleotide
polymorphisms in the tumour necrosis factor (TNF)-a and TNF-b genes of 56 patients with chronic
severe hepatitis B virus (HBV) infection, 71 patients who either had chronic mild HBV infection or who
were asymptomatic carriers, and 90 healthy controls. The serum TNF-a concentrations in patients with
chronic severe HBV infection were compared to those of 30 healthy controls by radioimmunoassay. The
frequencies of the TNF1 ⁄ 2 genotype and the TNF2 allele were greater in patients with chronic severe
HBV infection than in healthy controls (25% vs. 11.1%, p 0.015; 12.5% vs. 5.6%, p 0.036, respectively)
and patients with chronic mild HBV infection and asymptomatic carriers (25% vs. 8.8%, p 0.011; 12.5%
vs. 4.2%, p 0.015, respectively). Heterozygotes carrying the TNF2 allele had higher levels of serum TNF-
a than homozygotes for the wild-type allele among all patients with chronic severe HBV infection
(p < 0.01). The genotype distribution and allele frequency of TNF-b were similar for patients with
chronic severe HBV infection and healthy controls, but the frequency of the TNF-b*2 ⁄ 2 genotype in
patients with chronic mild HBV infection and asymptomatic controls was lower than for healthy
controls (9.9% vs. 22.4%, p 0.043) or patients with chronic severe HBV infection (9.9% vs. 26.8%,
p 0.043), although this was not signiﬁcant after correction for multiple testing. It was concluded that
TNF-a gene polymorphisms may play an important role as a host factor in the progression of HBV
infection.
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is
prevalent in China and is a major public health
problem. The reason why the spectrum of HBV
infection ranges from chronic asymptomatic car-
riage to chronic mild or severe hepatitis is still
unknown. In addition to HBV strain variation,
emerging evidence suggests that host factors,
especially genes related to immunity, might play
an important role in the pathogenesis of HBV
infection and might affect the clinical course, the
therapeutic response and the prognosis of the
disease. It has been suggested that the human
leukocyte antigenic (HLA) genes [1] and some
cytokine genes associated closely with immune
reactions, e.g., the tumour necrosis factor (TNF),
interleukin-1 and interleukin-10 genes [2], may be
important.
The TNF-a and TNF-b genes are located within
the highly polymorphic major histocompatibility
complex (MHC) III gene region, and many poly-
morphisms within the TNF gene cluster have
been identiﬁed. For example, a single-nucleotide
polymorphism (SNP) at position ) 308 in the
TNF-a promoter results in two allelic forms, one
in which G deﬁnes the common allele TNF1, and
another in which A deﬁnes the uncommon allele
TNF2 [3]. Another G ﬁ A transition in the ﬁrst
intron of TNF-b also produces two allelic forms,
TNF-b*1 and TNF-b*2. It has been reported that
the SNPs at the ) 238 and ) 308 loci of the TNF-a
promoter, and at the ) 252 locus of the ﬁrst intron
of TNF-b, can inﬂuence production of TNF at the
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transcriptional level [4], and these SNPs have
been correlated with sepsis [5–8], malaria [9] and
mucocutaneous leishmaniasis [10]. It is not yet
known whether these SNPs are associated with
HBV infection. The present study examined the
distribution of SNPs among patients with various
clinical types of chronic HBV infection and
determined the corresponding serum TNF levels.
PATIENTS AND METHODS
Study subjects
Ninety healthy controls (62 males and 28 females; mean age
38.3 ± 11.1 years) were blood donors from Changsha or
medical staff from our hospital. Fifty-six chronic severe HBV
infection patients (51 males and ﬁve females; mean age
35.7 ± 10.1 years) were enrolled from the infectious disease
ward of Central South University Xiangya Hospital between
October 2002 and January 2003. Seventy-one chronic mild HBV
infection patients and asymptomatic carriers (ASCs) (58 males
and 13 females; mean age 32.4 ± 14.2 years) with consistently
normal liver function test results were outpatients during the
same period.
None of the patients enrolled were infected with hepatitis
A, C or E viruses, and their diagnoses complied with the
diagnostic criteria of the 2000 Xi’an viral hepatitis management
scheme [11]. According to this scheme, viral hepatitis is
divided into several clinical types as follows: (1) acute
hepatitis, deﬁned as acute non-icterus type and acute icterus
type; (2) chronic hepatitis; (3) severe hepatitis, divided accord-
ing to the course of the disease into acute severe hepatitis,
sub-acute severe hepatitis or chronic severe hepatitis; (4)
cholestatic hepatitis; or (5) hepatitis with cirrhosis. The
detailed diagnostic criteria for chronic hepatitis and chronic
severe hepatitis were as follows.
Chronic hepatitis required a clinical course of acute virus
hepatitis of > 6 months, or a history of HBV or hepatitis D
virus infection, or a history of being an HBV carrier with
symptoms or signs of hepatitis and abnormal hepatic function
on this occasion. Even with an unclear date of onset, or
without a history of previous hepatitis, a case was diagnosed
as chronic hepatitis if the patient’s liver histology results
indicated chronic hepatitis after a general analysis of symp-
toms, signs, and serological and ultrasound evidence. To
reﬂect the degree of liver injury, chronic hepatitis was
subtyped as: (1) mild, with minimal or absence of clinical
symptoms and signs, and only one or two abnormal liver
function test results; (2) moderate, with clinical symptoms,
signs and laboratory ﬁndings midway between those of the
mild and severe subtypes; or (3) severe, if the patient had
obvious and consistent symptoms of hepatitis, such as fatigue,
loss of appetite, ﬂatulence, yellow-stained urine and loose
stool, accompanied by the appearance of liver disease, liver
palms, spider angioma and splenomegaly, with other causes
excluded and without portal hypertension. Laboratory ﬁnd-
ings in such cases included persistently or intermittently
elevated serum alanine aminotransferase and ⁄ or aspartate
aminotransferase levels, decreased plasma albumin or albu-
min ⁄globulin ratios, or obvious elevated c-globulin. In addi-
tion, patients with a plasma albumin concentration of £ 32 g ⁄L,
a serum bilirubin concentration of >5-fold the normal upper
limit, prothrombogen activity of 40–60%, or a cholinesterase
level of £ 4500 U ⁄L, were diagnosed as having severe chronic
hepatitis. Reference levels for laboratory ﬁndings used in the
diagnosis of chronic hepatitis are listed in Table 1. Ultrasound
ﬁndings can also be considered in the diagnosis of chronic
hepatitis.
Chronic severe hepatitis required: (1) a history of chronic
hepatitis or cirrhosis; (2) a history of chronic carriage of HBV;
(3) signs of chronic liver disease, such as liver palm and
spinder neavi, image abnormality, such as thickness of spleen,
and altered plasma biochemistry, such as elevated c-globulin
level, and decreased or even inverted albumin ⁄globulin ratio;
or (4) liver biopsy histology ﬁndings typical of chronic
hepatitis.
DNA was extracted from all individuals by means of
conventional phenol–chloroform procedures and was stored at
4C. Sera from patients with chronic severe HBV infection and
from healthy controls were stored at ) 20C, and radioimmu-
noassay was used to determine serum TNF-a levels.
TNF-a promoter polymorphisms
A 107-bp fragment containing the ) 308 locus of the TNF-a
gene promoter was ampliﬁed with forward primer 5¢-AG
GCAATAGGTTTTGAGGGCCAT-3¢ and reverse primer
5¢-TCCTCCCTGCTCCGATTCCG-3¢ [12] in a ﬁnal volume of
20 lL containing 50–100 ng of genomic DNA, 10 pmol of each
primer, 1 U of Taq enzyme, 75 mM Tris-HCl (pH 8.8), 20 mM
(NH4)2SO4, Tween-20 0.01% v ⁄v, 200 lM dNTPs and 2 mM
MgCl2. PCR conditions were 94C for 5 min, followed by 35
cycles of 94C for 60 s, 57C for 30 s and 72C for 60 s, with a
ﬁnal extension at 72C for 10 min. PCR products were digested
with 4 U of NcoI at 37C for 16 h, and then analysed by silver
staining following electrophoresis on non-degraded polyacryl-
amide 10% w ⁄v gels.
TNF-b polymorphisms
A 740-bp fragment containing the ) 252 locus of the TNF-b
gene was ampliﬁed with forward primer 5¢-CCGTGCTTCGT
GCTTTGGACTA-3¢ and reverse primer 5¢-AGAGCTGGTGG
GGACATGTCTG-3¢ [13] in the reaction mix described above.
PCR conditions were 94C for 5 min, followed by 32 cycles
involving denaturation at 94C for 60 s, with annealing for 30 s
at temperatures decreasing every two cycles to 69C, 66C,
63C, and 60C, followed by 57C for 24 cycles, and extension
Table 1. Reference values for laboratory ﬁndings in the
diagnosis of chronic hepatitis B virus (HBV) infection
Test Mild HBV Moderate HBV Severe HBV
ALT and ⁄ or AST
(IU ⁄L)
£ 3-fold normal > 3-fold normal > 3-fold normal
Bilirubin (lM) £ 2-fold normal > 2–5 fold normal > 5-fold normal
Albumin (g ⁄L) ‡ 35 35–32 £ 32
A ⁄G ‡ 1.4 1.4–1.0 < 1.0
Electrophoresis of
c-globulin (%)
£ 21 21–26 ‡ 26
Prothrombogen
activity (%)
> 70 70–60 60–40
Cholinesterase (U ⁄L) > 5400 5400–4500 £ 4500
ALT, alanine aminotransferase; AST, aspartate aminotransferase; A ⁄G, albu-
min ⁄ globulin ratio; IU, international unit.
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at 72C for 60 s, with a ﬁnal extension at 72C for 10 min. The
PCR products were then digested as described above and
analysed under ultraviolet light following electrophoresis on
agarose 1.7% w ⁄v gels and staining with ethidium bromide.
Statistical analysis
Student’s t-test was used to compare groups of numerical data,
while the chi-square test was used for genotype and allelic
gene frequency comparisons. Since the genotypic and allelic
distributions of polymorphism markers were compared
between healthy subjects and two diagnostic groups of
patients, a Bonferroni correction was applied to correct for
multiple testing (with a level of signiﬁcance set at
a< 0.05 ⁄ 2 = 0.025). All statistical tests were performed with
SPSS software v. 10.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The distribution of TNF-a promoter genotype and
allele frequencies is shown in Table 2. There were
no signiﬁcant differences in the frequencies of
TNF1 ⁄ 2 genotypes and TNF2 allelic genes
between healthy controls and patients with chro-
nic mild HBV infection and ASCs. However, the
TNF1 ⁄ 2 gene type frequency among patients with
chronic severe HBV infection was signiﬁcantly
higher than that for healthy controls (25% vs.
11.1%; p 0.015) or for patients with chronic mild
HBV infection and ASCs (25% vs. 8.8%; p 0.011).
Similarly, the frequency of the TNF2 allelic gene
was also signiﬁcantly higher than that for healthy
controls (12.5% vs. 5.6%; p 0.036) and the patients
with chronic mild HBV infection and ASCs
(12.5% vs. 4.2%; p 0.015).
Serum TNF-a and bilirubin levels in chronic
severe HBV infection patients with different gen-
otypes were signiﬁcantly higher for TNF1 ⁄ 2
heterozygotes than for TNF1 ⁄ 1 homozygotes
(2.79 vs. 3.28 ng ⁄mL, p 0.006, and 501.99 vs.
671.89 lmol ⁄L, p 0.003, respectively; Table 3).
There were no signiﬁcant differences in the TNF-
b genotype and allelic frequency distribution
between patients with chronic severe HBV infec-
tion and healthy controls (Table 4). However, the
TNFb*2 ⁄ 2 genotype frequency in the patients with
chronic mild HBV infection and ASCs was lower
than that for healthy controls (9.9% vs. 22.4%; p
0.043) and for patients with chronic severe HBV
infection (9.9% vs. 26.8%; p 0.043), although this
difference was not signiﬁcant following correction
for multiple testing (a 0.025).
DISCUSSION
TNFs are pleotropic cytokines, which include
TNF-a produced by mononuclear cells and TNF-
b produced by activated T-lymphocytes. Animal
model studies have shown that TNF plays an
important role in hepatocellular necrosis, while
clinical observations have indicated a correlation
between serum TNF-a levels and apparent clin-
ical types and prognoses. The TNF-a and TNF-b
genes are located within the highly polymorphic
class III region of the MHC gene region, and it has
been demonstrated that SNPs at positions ) 308
and ) 238 in the TNF-a gene promoter and 252 in
the ﬁrst intron of TNF-b can inﬂuence TNF
production at the transcriptional level. It is not
clear whether these SNPs can inﬂuence the
outcome of HBV infection. Hohler et al. [14]
suggested that SNPs might affect the effective
eradication of virus, but Miyazoe et al. [15] did
not ﬁnd any relationship between TNF gene
polymorphisms and the clinical course of chronic
HBV infection. However, Yee et al. [16] reported
that SNPs at the promoter ) 208 and ) 308 loci
correlated with the severity of tissue damage in
chronic hepatitis C virus infection.
The present study demonstrated that the
frequencies of TNF1 ⁄ 2 genotypes and TNF2
alleles did not differ signiﬁcantly between
healthy controls and chronic mild HBV infection
patients and ASCs, but were higher among
Table 2. TNF-a promoter genotype and allelic frequencies
in the groups investigated
Groups n
Genotype
p
Allele
pTNF1 ⁄ 1 TNF1 ⁄ 2 TNF1 TNF2
Controls 90 80 (88.9%) 10 (11.1%) 170 (94.4%) 10 (5.6%)
CSHB 56 42 (75.0%) 14 (25.0%) 0.015a
0.011b
98 (87.5%) 14 (12.5%) 0.036a
0.015b
CMHB
and ASCs
71 65 (91.5%) 6 (8.5%) 0.575c 136 (95.8%) 6 (4.2%) 0.585c
ASCs, asymptomatic carriers; CSHB, chronic severe hepatitis B; CMHB, chronic
mild hepatitis B; TNF, tumour necrosis factor.
aCSHB vs. healthy controls; as multiple comparisons were made, the Bonferroni-
corrected signiﬁcance level a was set to 0.025.
bCSHB vs. CMHB and ASCs.
cCMHB and ASCs vs. healthy controls.
Table 3. Mean serum TNF-a and bilirubin levels for
TNF1 ⁄ 1 homozygotes and TNF1 ⁄ 2 heterozygotes
Groups n TNF-a (ng/mL) Bilirubin (lmol/L)
TNF1 ⁄ 1 42 2.79 ± 1.03 501.99 ± 174.88
TNF1 ⁄ 2 14 3.82 ± 1.50a 671.89 ± 173.29b
TNF, tumour necrosis factor.
ap 0.006 and bp 0.003 (TNF1 ⁄ 1 homozygotes vs. TNF1 ⁄ 2 heterozygotes).
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patients suffering from chronic severe HBV
infection. These results suggest that these SNPs
may be associated with the pathogenesis of
chronic severe HBV infection. Further investiga-
tion of patients suffering from chronic severe
HBV infection revealed that the TNF-a serum
level in TNF1 ⁄ 2 heterozygotes was signiﬁcantly
higher than in the TNF1 ⁄ 1 homozygotes, and
that heterozygotes had an unfavourable progno-
sis. It seems conceivable that the substitution of a
single nucleotide (G ﬁ A) at this position
increased the production of TNF-a, and that
patients with HBV infection who carried the
relatively uncommon A allelic gene had a higher
level of TNF-a, with a greater immune response
and inﬂammation, which resulted in severe
hepatocellular damage and necrosis.
A further ﬁnding in the present study was that
the TNF-b genotype distribution showed no
signiﬁcant difference between chronic severe
HBV infection patients and healthy controls.
Similarly, the serum TNF-a and bilirubin levels
among chronic severe HBV infection patients
with different TNF-b genotypes showed no sig-
niﬁcant differences (data not shown). These
results suggest that this SNP may not have a
major effect on the pathogenesis of chronic severe
HBV infection. The TNFb*2 ⁄ 2 genotype frequency
among patients with chronic mild HBV infection
and ASCs was lower than that in healthy controls
and patients with chronic severe HBV infection,
although this difference was not signiﬁcant after
correction. However, the sample size was relat-
ively small, and further research with larger
patient numbers is required to verify the ﬁndings.
The TNF genes are located within a highly
polymorphic region of the MHC, and it also
remains to be determined whether the TNF gene
polymorphisms per se are related to the clinical
type of HBV infection, or whether this is simply
the result of HLA gene linkage imbalance.
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